Our innovators developed drug delivery and formulation technologies to bridge gaps in pharmaceutical sciences that are manifested by multiple unmet clinical needs.

Bone Marrow Drug Delivery Platform – Our proprietary peptide drug conjugate (PDC) demonstrated its advantages and benefits in delivering a cytoprotective molecule to protect hematopoietic stem and progenitor cells from chemotherapy or radiation induced myelotoxicity.

Reformulate Poorly Soluble Drugs to Injectables – Converting insoluble or poorly soluble small molecule drugs to highly soluble non-covalent molecular variants is a requirement to repurpose these oral drugs for use as emergency medicine (hemorrhage shock, sepsis).

Dual Biologic-Small Molecule Delivery System – The delivery of biologics and small molecule drugs in one system is achieved through uniquely engineered extracellular vesicles (e.g. exosome) clinically benefiting the management of wound biofilm.

With our partners, we collaboratively develop rapid companion wound diagnostic tests to facilitate patient management at the point of care, and develop a revolutionary AL-aided rapid sterility test in biomanufacturing quality control. These auxiliary products and solutions enhance the commercial values of our primary pharmaceutical technologies.